The innate immune system is an essential component of our defences to trauma and injury. But at the same time, it is one of the principal causes of morbidity and mortality in critical care [1] [2] [3] 
Introduction
The innate immune system is an essential component of our defences to trauma and injury. But at the same time, it is one of the principal causes of morbidity and mortality in critical care [1] [2] [3] . This outcome is especially dramatic in severe haemorrhage, because after losing over 50% of the blood volume, the system is unable to re-establish tissue perfusion. Thus, resuscitation fluids are classically designed to restore circulatory volume and tissue perfusion but they fail to prevent inflammatory responses during resuscitation. Characteristic inflammatory cytokines such as tumour necrosis factor (TNF) and high mobility group B protein-1 (HMGB1) contribute to lethal cardiovascular shock during resuscitation [2] [3] [4] . TNF diffuses in the bloodstream and produces a fatal cardiovascular collapse [4] . [5] [6] [7] . Extracellular HMGB1 sustains inflammatory responses [5] producing abrupt cardiac standstill [8] , intestinal derangement [9] and acute lung injury [10] . For these reasons, there is a major interest in inhibiting the production of these factors during resuscitation.
TNF is a sufficient and necessary mediator of 'haemorrhagic shock' because: (i) it is found in patients and experimental models of 'haemorrhagic shock'; (ii) TNF may contribute to the lethality of haemorrhagic shock; and (iii) TNF neutralization attenuates cardiovascular shock. In addition to TNF, recent studies indicated that HMGB1 plays an important role in haemorrhagic shock. HMGB1 was originally identified as a nuclear DNA-binding protein that functions as a structural co-factor. However, during cellular damage or necrosis, HMGB1 is liberated into the extracellular milieu where it functions as an inflammatory cytokine
The nervous system is an important regulator of the immune system, and neuronal anti-inflammatory mechanisms have been selected by evolution to modulate inflammatory responses [1] . These mechanisms can provide a major advantage for novel pharmacological anti-inflammatory strategies to control systemic inflammation [1, 11] . We reported that the parasympathetic nervous system restrains systemic inflammation via the vagus nerve [1, [11] [12] [13] . Electrical stimulation of the vagus nerve inhibits serum TNF levels in wild-type but not in alpha7nAChR-knockout mice [14, 15] . However, the anti-inflammatory potential of this mechanism is limited by the capacity of the vagus nerve to release acetylcholine and the neuronal innervation of specific organs [15] . Thus, we studied the anti-inflammatory potential of acetylcholine, the principal neurotransmitter of the vagus nerve. Acetylcholine inhibits the production of both TNF and HMGB1 in macrophages via the alpha7 nicotinic acetylcholine receptor (nAChR) [12] [13] [14] . In vivo, treatment with nicotine, a more selective cholinergic agonist, inhibits serum TNF and HMGB1 levels and improves survival in experimental models of systemic inflammation [12, 16] . Nicotine has been used in several clinical trials including inflammatory bowel disorders [17] , but its therapeutic potential is limited by its collateral toxicity. We proposed that alpha7nAChR-agonists could avoid the collateral toxicity of nicotine [1, 11, 13] . GTS is a characteristic alpha7nAChR-agonist, has been used in clinical trials and has proven to be less toxic than nicotine [18, 19] . GTS has been used in clinical trials to target neuronal alpha7nAChR in the brain of patients with Alzheimer's disease [20] . These studies showed a limited effect of GTS on the central nervous system potentially due to its limited ability to cross the blood-brain barrier. From an immunological perspective, this characteristic is an advantage to use GTS in the periphery and avoid secondary effects on the central nervous system. In contrast to nicotine, GTS has no effect on locomotor activity or on dopamine turnover indicating that it is less toxic than nicotine [18, 19] . Thus, we reasoned that GTS would represent a promising supplement to control systemic inflammation during resuscitation.
Alpha7 cholinergic-agonist prevents systemic inflammation and improves survival during resuscitation
Recently, we reported that similar to vagus nerve stimulation, nicotine inhibits TNF and HMGB1 production from macrophages via alpha7nAChR [12] . Here, we tested the ability of the alpha7-agonist, GTS, to control systemic inflammation during resuscitation. Hextend was used as the control resuscitation fluid because recent studies indicate that it prevents multiple organ injury [21] and improves short-time survival as compared with saline solution [22] . Hextend is a novel plasma volume expander containing 6% hydroxyethyl starch in Ringer's lactate [23] 
Statistical analyses

All data in the figures and text are expressed as mean Ϯ standard deviation (SD). Statistical analyses were performed using the one-way
Results
Alpha7nAChR-agonist improved survival during resuscitation
Haemorrhagic shock required withdrawing 21 
Adult male Sprague-Dawley haemorrhagic rats received no resuscitation (NR) or were resuscitated with 15 ml/kg (i.v.) Hextend (HEXT) or Hextend supplemented with GTS (GTS). (A) Arterial blood pressure was recorded during haemorrhage and the resuscitation treatment. (B) All animals without resuscitation treatment (NR; n ϭ 10) died within the first 5 hrs after haemorrhage with an average time of death of 161 Ϯ 26 min. Resuscitation with Hextend allowed the animals to restore normal blood pressure and tissue perfusion, and yet 90% of the animals died (n ϭ 9). Resuscitation with Hextend supplemented with GTS (GTS) statistically protected all the animals (n ϭ 7/group). (C) Treatment with 2 (GTS2), 0.2 mg/kg (GTS.2), but not 0.02 mg/kg (GTS02) GTS induced a statistically significant protection as compared with Hextend solution alone. P Ͻ 0.05 survival logrank test versus NR (*) or HXT(#).
Hextend; n ϭ 7). GTS improved survival in haemorrhagic shock in a concentration-dependent manner (Fig. 1C) (Fig. 2F) . Together, these results indicated that the therapeutic potential of GTS was not due to these mechanisms.
Because our previous studies indicated that the vagus nerve controlled systemic TNF responses via alpha7nAChR, we reasoned that the alpha7-agonist will produce a similar effect. Indeed, the most significant effects of GTS were in inhibiting systemic TNF levels. Haemorrhage induced a systemic TNF response that was not affected by resuscitation with Hextend (Fig. 3A) (Fig. 4) (Fig. 4D) .
Our results suggest that GTS may inhibit systemic and cardiac TNF levels by inhibiting TNF transcription in the spleen similar to what we described in experimental models of sepsis [15] . We analysed mRNA TNF levels in the heart and the spleen by real-time PCR (Fig. 5) . Haemorrhage increased mRNA TNF levels in both the heart and the spleen as analysed by real-time
PCR. As compared with Hextend, GTS inhibited NF-B and decreased mRNA TNF levels in the spleen but not in the heart. In order to determine whether the inhibition of splenic TNF is sufficient to account for the anti-inflammatory potential of GTS, we analysed the pharmacological implications of the spleen during resuscitation.
Pharmacological implications of the spleen in resuscitation
Our previous studies indicated that both vagus nerve stimulation and treatment with nicotine attenuated systemic TNF levels in sham but not in splenectomized animals [15] . We studied the pharmacological implications of the spleen during resuscitation using splenectomized animals with haemorrhage. (Fig. 6B) . However, the anti-inflammatory
Blood chemistry analyses showed that haemorrhage in splenectomized animals induced similar uraemia, metabolic acidosis and hyperglycaemia as compared to normal animals (data not shown). Again, the most significant effects of GTS were found in systemic TNF levels. Unlike systemic inflammation during endotoxemia, splenectomy actually exacerbated serum TNF levels during resuscitation (Fig. 6A). These higher serum TNF levels correlated with higher TNF levels in the liver but not in the lung or the heart. These results reveal a fundamental difference between the systemic inflammatory responses in endotoxemia and haemorrhage. The pattern of TNF expression during resuscitation in splenectomized animals is similar to that of non-splenectomized animals. More significant, GTS significantly inhibited systemic TNF levels in splenectomized animals
Fig. 2 Blood chemistry analyses during resuscitation. Blood from control adult male Sprague-Dawley rats, or haemorrhagic animals without resuscitation treatment (NR) or resuscitated with 15 ml/kg (i.v.) Hextend (HXT) or Hextend containing GTS (GTS) was collected at 2 hrs after the haemorrhagic load to analyse (A) blood urea nitrogen (BUN), (B) pH, (C) the anion gap (AnGap), (D) chloride (Cl), (E) bicarbonate (HCO3) and (F) Glucose. * represents P Ͻ 0.01 versus control (n ϭ 4/group; one-way ANOVA with Bonferroni's corrections). potential of GTS was lower than in non-splenectomized animals particularly in the liver. However, unlike vagus nerve stimulation or treatment with nicotine, GTS significantly inhibited serum TNF levels as well as TNF levels in the lung and the heart of splenectomized animals. These results indicate that GTS might provide a significant advantage as compared with non-specific cholinergic agonists to control systemic inflammation particularly in those patients with an injured or compromised spleen.
Fig. 3 GTS inhibits systemic TNF response during resuscitation. Blood and organs from control or haemorrhagic animals without (NR) or with resuscitation with Hextend (HXT) or Hextend supplemented with GTS (GTS) were analysed at 2 hrs to determine TNF protein concentration in the (A) serum, (B) lung, (C) liver, (D) heart and (E) spleen. * represents P Ͻ 0.05 versus HXT (n ϭ 4/group; one-way ANOVA with Bonferroni's corrections).
Alpha7nAChR-agonist inhibited systemic HMGB1 response and PARP activation during haemorrhage
HMGB1 is a characteristic marker of cellular damage that can act as a cardiodepressant factor causing acute lung injury and abrupt cardiac standstill [7, 25] . Haemorrhage induced a systemic HMGB1 response that was not prevented by resuscitation with Hextend (Fig. 7A) . However, one of the most significant effects of GTS was inhibiting systemic HMGB1 response during resuscitation. These results were particularly significant as no serum HMGB1 was found in those animals resuscitated with Hextend containing GTS. Because recent studies associated HMGB1 with liver damage during reperfusion [5, 26] and PARP appears to regulate HMGB1 secretion [27] and contributes to haemorrhagic shock [28] [29] [30] [21] and improves survival as compared with saline [22] . Third, the animals were followed for up to 7 Physiological anti-inflammatory mechanisms represent efficient systems selected by evolution to control inflammation and provide significant opportunities for novel anti-inflammatory strategies [1, 11, 13] . The vagus nerve restrains systemic inflammation in wild-type but not in alpha7-knockout mice [14, 15] . Both, acetylcholine and nicotine control the production of inflammatory cytokines in macrophages via the alpha7 nicotinic receptor [12, 14] . Treatment with nicotine inhibits serum TNF and HMGB1 levels and improves survival in experimental models of systemic inflammation [12] . Despite its clinical implications, the anti-inflammatory potential of cholinergic agonists is underestimated due to the collateral toxicity of nicotine including addiction, tachycardia and arrhythmia. We proposed that alpha7nAChR-agonists might represent a promising pharmacological strategy to control systemic inflammation and avoid collateral toxicity [1, 11, 13] . This hypothesis is consistent with recent studies indicating that individual cholinergic receptors mediate specific properties of nicotine. Thus, ␣7nAChR-agonists are expected to avoid nicotineinduced addiction [31] , locomotor activity [32] , tumourigenesis [33] , autonomic dysfunction or allodynia [34] , which appear to be mediated by other nicotinic receptors namely ␤2nAChR [32] , ␣3nAChR [33] , ␣4nAChR [31] or ␣5nAChR [34] , respectively. [18, 19] . GTS had no effect on locomotor activity in mice or dopamine turnover in rats. In contrast, nicotine produced a biphasic effect on locomotor activity [18] . These results prompt the potential use of GTS to avoid collateral toxicity of unspecific agonists [35, 36] .
, we analysed the effects of GTS on hepatic PARP activity. Haemorrhage activates hepatic PARP, and resuscitation with Hextend did not prevent it. However, resuscitation with Hextend supplemented with GTS inhibited PARP activation (Fig. 7B). Similar results were observed in other organs such as the spleen (data not shown). It is noteworthy that both serum HMGB1 levels and hepatic PARP activity correlated and the activity levels in animals resuscitated with GTS were similar to that in control animals.
Discussion
Conventional resuscitation fluids are designed to re-establish blood pressure and tissue perfusion, but they fail to prevent lethal inflammatory responses during resuscitation. For instance, resuscitation with Hextend re-established blood pressure and tissue perfusion, but still 90% of the animals died within the first 6 hrs
Fig. 4 GTS inhibits splenic RelA but not RelB NF-B in vivo during resuscitation. Organs from control (C) or haemorrhagic animals without (NR) or with resuscitation with Hextend (HXT) or Hextend supplemented with GTS (GTS) were collected at 2 hrs to analyse NF-B during resuscitation in the (A) heart, (B) liver and (C, D) spleen. Both canonical p65RelA (A-C) and alternative RelB (D) NF-B binding to
GTS (3-[(2,4-dimethoxy)benzylidene]-anabaseine) is a characteristic alpha7nAChR-agonist, already used in clinical trials and proven less toxic than nicotine
GTS inhibited systemic HMGB1 levels during resuscitation. Originally described as an intracellular protein, HMGB1 can be released into the extracellular milieu where it functions as a proinflammatory cytokine [2, 5, 37, 38] . Extracellular HMGB1 acts as a pro-inflammatory cytokine that activates immune cells and sustains inflammatory responses [5] contributing to abrupt cardiac standstill [8] , acute lung injury [10] and intestinal derangement [9] . HMGB1 appears to be a pharmacologic target for haemorrhagic shock as: (a) Serum HMGB1 levels are increased in patients with haemorrhagic shock [39] ; and (b) Inhibition of HMGB1 activity with neutralizing antibody significantly decreased liver damage after ischaemia and reperfusion [26] . Our previous studies supported HMGB1 as a late pharmacologic target for systemic inflammation, because it appears in the serum at 18-24 hrs after the induction of sepsis. However, this study now shows 'early' serum HMGB1 levels at 2 hrs after haemorrhage [40, 41] . Recent studies also reported 'early' extracellular HMGB1 release after hepatic ischaemia/reperfusion [26] . These differences between 'late' secretion in sepsis and 'early' release in haemorrhage may be explained by two different mechanisms of HMGB1 release/ production [5] . The first mechanism may be a time-consuming 'active secretion' from immune cells to act as a pro-inflammatory cytokine during an immunologic challenge such as sepsis [42] . The second mechanism may be the 'passive release' of HMGB1 from damaged or necrotic cells during haemorrhage. In this haemorrhagic scenario, HMGB1, an intracellular protein, represents an optimal signal to recognize tissue damage and initiate reparative responses [43] . From an immunological perspective, HMGB1 represents a characteristic 'necrotic marker' or damageassociated molecular pattern (DAMP) molecule [44, 45] . This emerging family of specific intracellular proteins represents optimal chemotactic markers selected by the innate immune system to recognize tissue damage and initiate reparative responses [46, 47] [28] [29] [30] 48] . Of special note is the correlation between PARP inhibition and systemic HMGB1. PARP inhibition can explain the regulation of systemic HMGB1 as PARP contributes to cell death via necrosis [49, 50] and PARP inhibitors prevent HMGB1 release in necrotic cells [27] . Furthermore, because PARP also regulates NF-B activation and inflammatory cytokines [30] , PARP inhibition may mediate the anti-inflammatory effects of cholinergic agonists via the alpha7nAChR.
Our previous studies indicated that the spleen is a major source of serum TNF and inhibition of TNF production in the spleen can prevent cardiovascular shock in endotoxemia [15] . The vagus nerve and non-specific cholinergic agonists prevent systemic inflammation during endotoxemia in normal but not in splenectomized animals [15] 
